Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future. Eli Lilly (LLY 1.51%) is the most valuable healthcare company in the world, with a market cap of around $950 billion. If you're worried you missed the boat on Eli Lilly, you shouldn't be, as there are other healthcare companies involved in the development of GLP-1 drugs, which could generate some strong growth in the future. By comparison, investors today are paying a forward P/E of 32 for Eli Lilly stock. Amgen is a cheap buy in comparison to Eli Lilly, and with a possible catalyst that could drive its share price much higher, it could make for an appealing healthcare stock to buy right now.